ROYALTY PURCHASE AGREEMENT dated as of July 14, 2021 among KUROS BIOSCIENCES AG, as Swiss Parent KUROS US LLC, as US Parent KUROS ROYALTY FUND (US) LLC, as Seller, and XOMA (US) LLC, as PurchaserRoyalty Purchase Agreement • November 4th, 2021 • XOMA Corp • Pharmaceutical preparations • New York
This ROYALTY PURCHASE AGREEMENT (this “Agreement”) dated as of July 14, 2021 (the “Effective Date”), is among KUROS BIOSCIENCES AG, a corporation organized and existing under the laws of Switzerland, located at Wagistrasse 25 Schlieren, 8952 Switzerland (“Swiss Parent”), KUROS US LLC, a Delaware limited liability company and a wholly-owned subsidiary of Swiss Parent (“US Parent”), KUROS ROYALTY FUND (US) LLC, a Delaware limited liability company and a wholly-owned subsidiary of US Parent (“Seller”, and together with Swiss Parent and US Parent, collectively, the “Seller Parties” and, individually, each a “Seller Party”) and XOMA (US) LLC, a Delaware limited liability company with its principal place of business at 2200 Powell Street, Suite 310, Emeryville, California 94608 (“Purchaser”).
